ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: pain

Sanofi, Regeneron Expand Testing of Potential Coronavirus Treatment

Reuters Staff  |  March 31, 2020

(Reuters)—Sanofi and Regeneron Pharmaceuticals Inc. have expanded a clinical trial of their rheumatoid arthritis drug Kevzara (sarilumab) as a coronavirus treatment to patients outside the U.S. The companies said enrolments for the mid-to-late stage trial of sarilumab, an immune-system modifying drug known as a monoclonal antibody, have now started in Italy, Spain, Germany, France, Canada…

Filed under:Drug Updates Tagged with:clinical trialsCOVID-19Regeneron Pharmaceuticals Inc.Sanofisarilumab

Activating Yourself in the Time of Coronavirus

Amish J. Dave, MD, MPH  |  March 30, 2020

A timely and personal appeal to all those who can to become or remain civically active in this critical time.

Filed under:OpinionProfessional TopicsSpeak Out Rheum Tagged with:COVID-19

Inflammation & Psych Issues: A Look at Potential Co-Morbidity

Mike Fillon  |  March 30, 2020

Rheumatic disease affects not just the body, but can also compound psychiatric disturbances, including depression, anxiety, fatigue and more, possibly making the underlying disease worse…

Filed under:Conditions Tagged with:comorbiditiesinflammationmindpsychiatric

Enemy at the Gates: The Emerging Threat of COVID-19

Philip Seo, MD, MHS  |  March 23, 2020

On Dec. 30, 2019, an ophthalmologist named Li Wenliang notified his colleagues about an illness that was reminiscent of severe acute respiratory syndrome (SARS) in a city in the Hubei province of China called Wuhan. As an ophthalmologist, this was not directly relevant to his practice; he merely wanted to warn colleagues that they might…

Filed under:ConditionsOpinionProfessional TopicsRheuminationsSpeak Out Rheum Tagged with:COVID-19Philip SeoRheuminationsSeo

Axial Spondyloarthritis & Exercise: Should axSpA Patients Exercise?

Mike Fillon  |  March 23, 2020

Two experts weigh in on whether & how axial spondyloarthritis patients should exercise…

Filed under:Axial SpondyloarthritisConditions Tagged with:2019 ACR/ARP Annual Meetingaxial spondyloarthritis (SpA)ExerciseExercise/physical therapy

Key Studies Highlighted: 2 Industry Veterans Discuss Their Favorite Annual Meeting Abstracts

Mike Fillon  |  March 19, 2020

ATLANTA—With more than 3,000 abstracts from 103 countries presented at the 2019 ACR/ARP Annual Meeting in November, it was impossible for attendees to view them all. However, two ACR/ARP veterans—Arthur Kavanaugh, MD, from the University of California, San Diego, and John Cush, MD, from UT Southwestern Medical School, Dallas—chose to tackle the nearly impossible task and…

Filed under:Axial SpondyloarthritisConditions Tagged with:2019 ACR/ARP Annual MeetingBiologicsburnouthyperuricemiamachine learningmacrophage activation syndromepregnancy

The Doctor Will See You Now: Legal & Regulatory Reforms Expand Telemedicine

Steven M. Harris, Esq.  |  March 17, 2020

In this time of COVID-19, you may be considering ways to deliver routine rheumatologic care via some form of telemedicine. Here are some of the legal considerations.

Filed under:Legal UpdatesProfessional Topics Tagged with:COVID-19telehealthtelemedicine

Pediatric Cases Require Special Considerations & Aggressive Treatment Plans

Thomas R. Collins  |  March 12, 2020

ATLANTA—Managing pediatric patients with rheumatic disease involves special considerations, such as developmental concerns and physiological traits that may affect dosing of medications, according to two experts. During a session at the 2019 ACR/ARP Annual Meeting, Courtney Kremer, ARNP, a pediatric nurse practitioner at the University of Iowa Stead Family Children’s Hospital, Iowa City, and Jessica…

Filed under:Biologics/DMARDsConditionsMeeting ReportsPediatric Conditions Tagged with:2019 ACR/ARP Annual Meetingjuvenile idiopathic arthritis (JIA)

A Public Health Approach to Arthritis

Thomas R. Collins  |  March 12, 2020

ATLANTA—Rheumatic diseases have been the subject of a range of public health campaigns and reports over the past decade, but improving their visibility remains a work in progress, a Centers for Disease Control and Prevention (CDC) expert said at the 2019 ACR/ARP Annual Meeting. A growing attention to pain and the opioid crisis may help…

Filed under:AnalgesicsConditionsMeeting Reports Tagged with:2019 ACR/ARP Annual MeetingCenters for Disease Control and Preventionopioid crisisPain Managementpublic health

Thoughtful Pediatric Care: Pediatric Cases Require Special Considerations & Aggressive Treatment Plans

Thomas R. Collins  |  March 9, 2020

In Canada, five provinces will now reimburse patients with plaque psoriasis who use risankizumab. Also, Canada Health has approved apremilast for treating adults with plaque psoriasis and psoriatic arthritis…

Filed under:Conditions Tagged with:2019 ACR/ARP Annual Meetingpediatric arthritisPediatric RheumatologyPediatrics

  • « Previous Page
  • 1
  • …
  • 84
  • 85
  • 86
  • 87
  • 88
  • …
  • 247
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences